Los Angeles Health News
Scroll down for most recent articles
The Beverly Hills Comprehensive Medical Group Announces Name Change
Dr. Jacobsen stresses that the practice will continue to provide primary and urgent care to patients. "If you are sick now, we are here to see you immediately," said Dr. Jacobsen. "We know our patients are busy and they deserve immediate access to the care that they need. That's why we never want to make patients wait to see a doctor." BHCMG welcomes patient walk-ins between 7 a.m. - 3 p.m., Monday through Friday. Patients will be seen by a board-certified physician in 30 minutes or less.
Dr. Tannaz Zahirpour D.O., has recently joined The Beverly Hills Comprehensive Medical Group, "I am board certified in family practice...I really enjoy treating the whole family. I love when I get to see Moms, Dads, and their children." Dr. Zahirpour's clinical interests include preventative medicine, adolescent medicine, women's
health, and dermatology. To facilitate treatment and prevention, patients are examined for more than just their immediate condition. "I have a holistic approach to medicine and try to treat the whole body and not just the ailment," said Dr. Zahirpour. "I take pride in being thorough with the care of my patients."
"We are thrilled to welcome Dr. Zahirpour to our practice, she is a tremendous asset," said Dr. Jacobsen. "From her extensive medical training to her compassionate approach to patient care, she brings many talents. Additionally, her unique method makes a big difference for each patient's health."
The office projects a positive energy and creates a personal camaraderie with patients. "I truly love when I get to know my patients on a first name basis, and make them part of our family at BHCMG," said Dr. Zahirpour. "It is important for me to teach my patients, and also learn from them every chance I get."
Prospective patients who wish to learn more about the services at The Beverly Hills Comprehensive Medical Group may contact the clinic by phone or visit the website.
CONTACT: The Beverly Hills Comprehensive Medical Group, 1-888-667-5235
To better reflect the practice's diverse array of medical services, The Beverly Hills Comprehensive Medical Group (BHCMG) will no longer be known as Executive ER. "Our new name is meant to reflect the diversity of services that we currently offer to the community," said chiropractor and founder Dr. Daniel Jacobsen. "We are proud to be a premier provider of both urgent medical care as well as complementary wellness services
such as weight loss and chiropractic care. Our new name reflects this integrated approach to medicine." The doctors at BHCMG collaborate with each other to promote overall wellness.
Study Links Autistic Behaviors to Enzyme
obsessive-compulsive and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits.
The researchers found that an enzyme, MMP-9, plays a critical role. MMP-9 is produced by brain cells. Too much MMP-9 activity causes synapses in the brain to become unstable, leading to functional deficits. So, working on mice, the researchers targeted MMP-9 as a potential therapeutic target in FXS and showed that genetically deleting MMP-9 favorably impacts key aspects of FXS-associated behaviors.
The study appears in the Journal of Neuroscience.
For more information, please visit: http://ucrtoday.ucr.edu/2394
Biomedical scientists at the University of California, Riverside have published a study today that sheds light on the cause of autistic behaviors in Fragile X syndrome (FXS), the genetic disorder that causes
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60
In June 2014, Ruthigen's Investigational New Drug (IND) application became effective following review by the U.S. Food and Drug Administration (FDA). Ruthigen is developing RUT58-60 as a safe and fast acting, broad spectrum and potent anti-infective drug candidate intended to be used as an adjunct therapy to systemic antibiotics for the prevention and treatment of infection associated with abdominal surgery.
"We are excited to begin a new chapter for Ruthigen with the initiation of human clinical testing of RUT58-60," said Hoji Alimi, Chairman, CEO and CSO of Ruthigen. "Treatment of our first subject with RUT58-60 is an important milestone and marks a transition for Ruthigen into a clinical-stage company." Mr. Alimi continued, "Patients undergoing abdominal surgery should not have to worry about the risk of infections associated with their procedures. At Ruthigen we believe the key to optimizing patient care is to focus on the prevention of infections in the hospital and outpatient surgical settings."
Following an independent data monitoring committee review, the Company plans to begin enrollment in a 150 patient, 28-day Phase 1/2 clinical trial using RUT58-60 within the abdominal cavity. The Phase 1/2 trial will be a controlled, double blind, randomized, and multi-centered study to evaluate the safety, tolerability, and potential efficacy of RUT58-60.
About Ruthigen, Inc. Ruthigen is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications. The Company's lead drug candidate, RUT58-60, is a broad-spectrum anti-infective that Ruthigen is developing for the prevention and treatment of infection in surgical and trauma procedures. The Company plans to complete its Phase I/II clinical trial in Q1 2015 and pending the successful completion of that trial, Ruthigen plans to conduct pivotal clinical trials. For more information, visit www.ruthigen.com.
About RUT58-60: RUT58-60 is a new chemical formulation containing hypochlorous acid, HOCl, with no hypochlorite, and utilizes other small molecule stabilizers. RUT58-60 is a broad-spectrum anti-infective drug candidate designed for prophylactic use during invasive surgical procedures. The drug has been shown in laboratory tests to eradicate both gram-positive and gram-negative bacteria, including antibiotic resistant bacteria within the first 30 seconds of contact. RUT58-60 was designed to improve patient lives, redefine infection control in surgical procedures and deliver cost savings to hospitals. RUT58-60 uses a mechanism of action designed to prevent emergence of bacterial resistance and improves patient safety by neither targeting specific bacterial cell membrane receptors nor exposing patient's vital organs to unnecessary systemic drugs. The Company's clinical program targets an initial $700M potential market in the prevention of infections associated with abdominal surgery. The Company believes the market for prevention of infection in the U.S. surgical market is estimated at $3B.
Ruthigen, Inc., (Nasdaq:RTGN) today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014.
UCLA faculty contribute to international study on the biology behind schizophrenia
Research identifies genes, pathways that could suggest new approaches to treatment
The study, the largest genomic study published on any psychiatric disorder to date, provides important new insights about the biological causes of schizophrenia, and it could lead to new approaches to treatment. The report was published in the July 22 online edition of the journal Nature.
"As recently as five years ago, we still lacked proof that mental disorders had a genetic basis," said Dr. Nelson Freimer, a UCLA professor of psychiatry and director of the UCLA Center for Neurobehavioral Genetics, who was part of the study. "This work now demonstrates unequivocally that at least 100 distinct genes contribute to schizophrenia. By providing the strongest evidence to date for the biological underpinnings of mental illness, this study is of historic importance."
Schizophrenia, a debilitating psychiatric disorder that affects approximately 1 percent of the world's population, is characterized by hallucinations, paranoia and a breakdown of thought processes, and it often emerges in the teens and early 20s. Its lifetime impact on individuals and society is high, both in terms of years of healthy life lost to disability and in terms of financial cost, with studies estimating that schizophrenia costs over $60 billion annually in the U.S. alone.
Despite the pressing need for treatment, there have been few innovations in drugs to treat schizophrenia for more than 60 years — in part because the disease's underlying biological mechanisms have not been understood. Current medications treat only the psychosis that is one of its symptoms but do not address its debilitating cognitive symptoms.
Since the dawn of genomic medicine in the early 2000s, schizophrenia research has focused on the disorder's genetic underpinnings, because it is so frequently hereditary. Previous studies have suggested that it is caused by the combined effects of many genes, and roughly two dozen locations of the chromosome have been found to be associated with the disorder.
The new study confirms those earlier findings and sheds new light on schizophrenia's genetic basis and underlying biology.
"These results firmly show a biological basis of schizophrenia, which should remove some of the remaining stigma that still surrounds the disease," said Roel Ophoff, a professor of human genetics and psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior who also contributed to the study. "It is remarkable to observe that the genetic architecture of schizophrenia is very similar to that of other heritable human diseases and traits. Our ability to detect genetic risk factors on this massive scale, which is providing a wealth of information, should give us hope to develop new treatments for schizophrenia."
The authors analyzed more than 80,000 genetic samples from people with and without schizophrenia. They identified 108 specific locations in the human genome associated with risk for schizophrenia, 83 of which had not previously been linked to the disorder.
The study implicates genes expressed in brain tissue, particularly those related to neuron and synapse function. Among them are genes active in the pathways that control the ability for neuronal synapses to change — a function essential to learning and memory.
Additionally, the researchers found a small number of genes associated with schizophrenia that are active in the immune system, a discovery that offers some support for a previously hypothesized link between schizophrenia and immunological processes. The study also found an association between the disorder and the region of the genome that holds a gene called DRD2, which produces the dopamine receptor targeted by all approved medications for schizophrenia. That finding suggests that other locations uncovered in the study may be targets for new therapies.
"By studying the genome, we are getting a better handle on the genetic variations that are making people vulnerable to psychiatric disease," said Dr. Tom Insel, director of the National Institute of Mental Health, which helped fund the study. "Through the wonders of genomic technology, we are in a period in which, for the first time, we are beginning to understand many of the players at the molecular and cellular level."
The study was conducted over several years by the Schizophrenia Working Group of the Psychiatric Genomics Consortium; it included 55 datasets from more than 40 different contributors, including Ophoff and Freimer, who genotyped their samples at UCLA. Ophoff was one of the founding principal investigators of the international collaboration, which was founded in 2007 to conduct broad-scale analyses of genetic data for psychiatric disease.
The PGC is currently genotyping new samples to further study schizophrenia, autism, bipolar disorder and other psychiatric diseases.
Core funding for the Consortium comes from the National Institute of Mental Health, along with numerous grants from governmental and charitable organizations, as well as philanthropic donations. Rita Cantor, a UCLA professor of human genetics, was also an author on the paper.
UCLA researchers were part of a multinational effort that has identified more than 100 locations in the human genome associated with the risk of developing schizophrenia.
Watchdog Group Files FDA Petition to Better Protect Drug Trial Participants
Unreliable Drug Testing Practices Put Clinical Trial Participants and Consumers At Risk, Contends the Center for Responsible Science
petition with the Food and Drug Administration (FDA) to update its informed consent regulations so that clinical trial participants will no longer be kept in the dark about the hazards they may unwittingly assume when they agree to participate.
Currently, drug manufacturers do not disclose to clinical trial participants that preclinical testing, which relies heavily on FDA-mandated animal testing, rarely predicts human drug response accurately. Failure to disclose this level of risk to human safety renders the FDA’s informed consent process faulty. Drug trial participants must receive meaningful warnings so they can decide for themselves if the uncertainties and risks of trial participation are warranted.
Many drugs that have appeared safe in animal studies have caused severe adverse reactions and death when given to humans. Because of a lack of published reports, it is unclear how many people suffer these consequences as a result of taking drugs administered in U.S. clinical trials. This uncertainty makes it even more important that the FDA update its regulations and issue proper warnings to trial participants.
“The FDA admits that 92 percent of drugs fail in humans even after the drugs tested well in preclinical studies,” said Mark Mazzarella, CRS’ lead counsel. “In light of the convincing evidence that human subjects are currently participating in clinical trials without a full understanding of the attendant risks, there is no public policy justification for a refusal by the FDA to act.”
Said CRS co-petitioner John Tessmer, a former clinical trial participant: “I do not believe that I should be asked to risk my health until I have been given the disclosure that this petition requests--that is, information that a reasonable person would need to make an informed decision with regard to the real risks posed by the clinical trial. I don’t believe anyone else should either.”
About the Center for Responsible Science: The Center for Responsible Science (CRS) is a California 501(c)(3) nonprofit organization. Its mission is to save lives by tackling the root causes of inefficient, outdated drug development. CRS works to expose and address issues threatening the health, public interest or well being of Americans. This informed- consent citizen petition is the first of several petitions CRS plans to file in an effort to update Food and Drug Administration policy. For more information, go to www.crs501.org.
The Center for Responsible Science (CRS), a nonpartisan, nonprofit watchdog group advocating for more modern and accurately predictive test methods for new-drug development, is warning the public that conventional drug testing may put the health of clinical trial participants and consumers at risk. CRS has filed a citizen